Matinas Biopharma Holdings Inc (MTNB)

[RealFooFighters]

You read my previous post!

- Authorized 1:2 - 1:15 RS (Jan ’21 / Expires January 26, ’22)

Could be, perhaps they shouldn't waste it, we'll know soon!

Regardless, zero change to valuation!

Conviction: Matinas check all the boxes:

- Sound Science!
- Viable Product/Platform (clinically de-risked)!
- Strong Competent Team! (No selling!)
- Financially Sound (Cash til ’24 & No debt!)
- Huge TAM’s (Realizable & Recurring)
- Broad/Long Patent/Knowledge Moat
- Reasonable Valuation (in some cases irrational :)

[Realcool11]

Seems they will announce a reverse split since deadline for that is 1/26.

[RealFooFighters]

Save the date - Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook

Matinas will host a conference call and live audio webcast on Tuesday, January 25th, at 8:30 a.m. ET to discuss the Company's business outlook for 2022. Dial-in and webcast details here:

Save the date - Matinas will host a conference call and live audio webcast on Tuesday, January 25th, at 8:30 a.m. ET to discuss the Company's business outlook for 2022. Dial-in and webcast details here: https://t.co/B4wDjQVWks $MTNB

— Matinas BioPharma (@MatinasBio) January 20, 2022

[RealFooFighters]

Save the date - Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook

Matinas will host a conference call and live audio webcast on Tuesday, January 25th, at 8:30 a.m. ET to discuss the Company's business outlook for 2022. Dial-in and webcast details here:

Save the date - Matinas will host a conference call and live audio webcast on Tuesday, January 25th, at 8:30 a.m. ET to discuss the Company's business outlook for 2022. Dial-in and webcast details here: https://t.co/B4wDjQVWks $MTNB

— Matinas BioPharma (@MatinasBio) January 20, 2022

[The Lawman]

Excellent analysis RealFoo.

[RealFooFighters]

Conviction that they check all the boxes:

- Sound Science!
- Viable Product/Platform (clinically de-risked)!
- Strong Competent Team! (No selling!)
- Financially Sound (Cash til ’24 & No debt!)
- Huge TAM’s (Realizable & Recurring)
- Broad/Long Patent/Knowledge Moat
- Reasonable Valuation (in some cases irrational :)

[RealFooFighters]

Getting interesting!

Pivotal Month! (Jan ’22)
- FDA discussions revealed ?
- EnACT Final Registration Phase ?
- NIH/NIAID LNC OralRem Phase 1 initiated ?
- Institutional Support/Accumulation !

Need $$’s to Broaden Pipeline/TAM!
- Trials currently funded by NIH & CFF
- Commercial Revenue ’23 ?
- BP Deals ?

Treasury (misc factoids)
- Outstanding Shares ~216M (Fully diluted ~250M)
- Valuation <$200M
- Cash ~$60M (No Debt)
- Qtly Burn ~$5M
- Last raise ~$50M @ $1.55 (Jan ’20)
- Authorized $200M Shelf (July ’20)
- Authorized 1:2 - 1:15 RS (Jan ’21 / Expires January 26, ’22)

[RealFooFighters]

Tuesday’s 2022 update, lot’s of moving parts, some stuff:

1) We want to hear feedback from the FDA meeting (hopefully no delays?), specifically;

A) Will they accept EnACT’s Phase 2 trial as a sufficient (e.g. registrational) to approve?
- Initially for Step-down (based on Cohort 1 & 2)
- Subsequently for Consolidation (based on 1-4)
- Ultimately for Induction (based on Cohort 4)
Or will they require a Phase 3 Trial (larger population/other geographies/US patients?)

B) Guidance on what's the fastest approval track possible (given they have multiple fast-track designations)?
- Matinas wants to know what the shortest point between A & B (regardless of what you call it!)

* Note: They already mentioned they expect a Phase 3 (all-in) trial for other IFI indications!

2) MAT2203 “Go to Market” Strategy/Funding?

3) NIH/UNC in vivo study update?

4) Genentech’s collaborations/next steps?

5) New Partners/Licensing deals (cash)?

6) Treasury Update (RS, Uplisting plans, ..)?

7) Complete 5-year MAT2203 data (Dec scheduled completion)

8) Update of MAT2501 Phase 1 / CFF next round funding?

[specopsman]

Check out Gilead press release on phase 1 trial of GS 5245.

[dhbuzz]

Friday was a VERY INTERESTING trade day,is something about to happen here?/

Monday,and next week may get REALLY EXCITING>WATCHING

[dhbuzz]

December 16 2021 - 06:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced that the independent Data and Safety Monitoring Board (DSMB) of the EnACT trial (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial) has completed a prespecified review of the third cohort and unanimously recommended progression to the fourth and final cohort of patients. Enrollment in the next randomized EnACT cohort, with 40 active-treatment patients, is expected to begin early first quarter 2022.
“Unanimous DSMB approval to proceed to cohort four in the EnACT trial is a strong statement that MAT2203 continues to exceed the prespecified efficacy and safety thresholds assessed in the first two cohorts,” said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma. “We have made significant progress advancing MAT2203 through clinical development, and the fourth cohort of EnACT represents a meaningful opportunity to further validate an all-oral treatment regimen with amphotericin B, and position MAT2203 as a potential first-line treatment for cryptococcal meningitis. Ultimately, our goal is to develop MAT2203 to become the preferred therapeutic option for the treatment of most invasive fungal infections and provide physicians and patients with an effective, convenient and safe oral formulation of one of the most potent antifungal agents available.”

“Our team continues to be pleased with the performance of oral MAT2203 for the treatment of cryptococcal meningitis,” commented David Boulware, M.D., M.P.H, Professor of Medicine at the University of Minnesota and Principal Investigator for the trial. “Cohort 3 of the ENACT trial tested whether starting with an all-oral regimen of amphotericin and flucytosine would be possible. Participants received 5 days of oral combination therapy before a scheduled switch to intravenous amphotericin. In this cohort with 10 participants receiving MAT2203, the direct antifungal therapy activity measured in cerebrospinal fluid continued to be above our pre-defined target threshold for success. We are excited to begin the fourth cohort testing the all-oral regimen of MAT2203 in a larger number of patients beginning in early January.”

“The continued progression of EnACT and the impressive data generated to date in this highly vulnerable patient population are a clear demonstration of how our LNC platform can unlock the full therapeutic potential of life-saving medicines,” remarked Jerome D. Jabbour, Chief Executive Officer of Matinas. “We believe this is further validation of how our proprietary technology can be used to overcome significant drug delivery challenges and we remain excited by the interest shown in the application of the LNC platform beyond anti-infective therapies.”

About the EnACT Study

[dhbuzz]

WATCH VERY CLOSELY

[dhbuzz]

https://humanevents.com/2021/12/01/remdesivir-expected-to-remain-effective-against-omicron-variant/

[dhbuzz]

WELCOME DECEMBER !

LETS DO THIS MATINAS!

[dhbuzz]

Heavy duty pre market...more news in the works???

LET'R RIP!!!!!!!!!!!!!!11

[vdt]

Yes, MTNB will have substantial movement UP
very very soon,and not just for the short term

[dhbuzz]

Its been a slow ride now for a while.I am looking forward to some substantial movement up very very soon,and not just for the short term..
GLTA

[vdt]

Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
October 21 2021 - 07:00AM
GlobeNewswire Inc.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced that it has dosed the first patient in a Phase 1 single ascending dose (SAD) pharmacokinetic study in healthy volunteers with MAT2501.

The Company expects to complete enrollment of the Phase 1 SAD study in the first quarter of 2022, with data anticipated during the second quarter of 2022. Pending successful completion of the Phase 1 SAD study, the Company expects to start a Phase 2 program in patients with nontuberculous mycobacterial (NTM) infections by the first quarter of 2023, following required longer-term preclinical toxicology studies to be conducted during 2022.

MAT2501 is being developed to potentially become the first oral aminoglycoside, with the application of Matinas’ proprietary LNC platform technology to the broad-spectrum antibiotic drug amikacin. Amikacin is a highly potent antibiotic used to treat chronic and acute bacterial infections, including problematic gram-negative infections.

Currently, amikacin’s use (IV or inhalation) is severely limited due to associated major side effects including nephrotoxicity and ototoxicity (hearing loss and potentially permanent impairment of balance), as well as inhalation complications with certain approved therapies.

“Following the robust data from MAT2203 in the EnACT trial announced in September 2021, MAT2501 now becomes our second clinical stage product candidate demonstrating the benefits of our LNC platform delivery technology in treating infectious diseases.

Our goal with MAT2501 is to develop the first oral aminoglycoside, which could transform the use of this important class of drugs,” stated Jerome D. Jabbour, Chief Executive Officer of Matinas. “At its core, our LNC platform facilitates intracellular delivery. We believe that MAT2501’s ability to orally, effectively, efficiently and safely deliver therapeutic levels of amikacin that specifically target the lung, without use-limiting toxicity, clearly distinguishes it from other available therapies for the treatment of NTM infections.

Furthermore, we believe that the ultimate applicability of MAT2501 will not be limited to the treatment of pulmonary infections, and we expect to evaluate its use in other, more acute bacterial infections, such as gram-negative infections, where the unmet medical need is significant and unfortunately growing due to a lack of effective therapies.”

This Phase 1 study is a double-blind, placebo-controlled, SAD study designed primarily to evaluate the safety, tolerability and pharmacokinetics of single ascending oral doses of MAT2501 in healthy adult subjects. Secondary objectives include the assessment of the effect of food on the pharmacokinetics of amikacin following a single oral dose of MAT2501.

Development of MAT2501 has been supported by a $4.2 million Therapeutics Development Award from the Cystic Fibrosis Foundation.

The U.S. Food and Drug Administration (FDA) has designated MAT2501 as a Qualified Infectious Disease Product (QIDP) and as an Orphan Drug for the treatment of NTM. If MAT2501 is ultimately approved by the FDA, the seven-year period of marketing exclusivity from orphan designation combined with the additional five years of marketing exclusivity provided by the QIDP designation, would provide for a potential total of 12 years of marketing exclusivity.

[dhbuzz]

[dhbuzz]

https://ih.advfn.com/stock-market/AMEX/matinas-biopharma-MTNB/stock-news/86086972/matinas-biopharma-announces-accomplished-biotechno

[dhbuzz]

https://abcnews.go.com/Health/fungal-disease-rise-west-possibly-tied-changing-climate/story?id=80582150

[dhbuzz]

https://centerforhealthjournalism.org/valleyfever/just-one-breath-valley-fever-costs-mount-patients-and-taxpayers

[dhbuzz]

October 14, 2021 - Congressional Valley Fever Task Force Co-Chair and Congressman Kevin McCarthy, along with Task Force Co-Chair and Congressman David Schweikert (AZ- 06), Congresswoman Karen Bass (CA-37), and Congressman Tom O’Halleran (AZ-01) introduced a bipartisan bill, the Finding Orphan-disease Remedies with Antifungal Research and Development (FORWARD) Act of 2021 (H.R. 5566), to combat Valley Fever.
Congressman Kevin McCarthy Reintroduces Central Valley ...
goldrushcam.com/sierrasuntimes/index.php/news/local-news/34115-congressman-kevin-mccarthy-reintroduces-central-valley-fever-bill-to-ultimately-find-a-vaccine-to-protect-californians
goldrushcam.com/sierrasuntimes/index.php/news/local-news/34115-congressm…

[dhbuzz]

https://www.nasdaq.com/articles/matinas-biopharma-holdings-inc.-mtnb-upgraded-to-buy%3A-heres-what-you-should-know-2021-10

[RealFooFighters]

Oral LNC/Remdesivir may not only be more efficacious, but safer!

Which would you opt for?
- Remdesivir blocks replication
- Molnupiravir propagates errors in replication

"both molnupiravir and Veklury are incorporated by the viral RNA polymerase, with molnupiravir being a viral genome mutagen and Veklury blocking replication done by the polymerase"

"Side effect concerns have been raised about whether molnupiravir could be metabolised into a precursor of DNA, Swanstrom said, explaining it could enter the host cell nucleus, leading to oncogenesis."

https://www.clinicaltrialsarena.com/comment/ridgeback-mercks-molnupiravir-for-covid-19-has-moa-administration-advantages-but-phase-iia-faces-execution-obstacles-may-have-value-gaps/

[RealFooFighters]

Merck's Oral CV19 Therapeutic - Black Box?

https://www.drugdiscoverytrends.com/early-safety-concerns-accompanied-mercks-molnupiravir-the-first-potential-oral-covid-19-therapy/

[vdt]

Just wait for awhile and BUY again.
-------------------------------------

The 5 analysts offering 12-month price forecasts for Matinas BioPharma Holdings Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 0.90. The median estimate represents a +138.10% increase from the last price of 1.26.

[RealFooFighters]

Change your travel plans

11th International Cryptococcus and Cryptococcosis Conference (ICCC) has been rescheduled for January 9-13, 2023 in Kampala, Uganda.

11th International Cryptococcus and Cryptococcosis Conference (ICCC) has been rescheduled for January 9-13, 2023 in Kampala, Uganda. #IDtwitter #HIVTwitter
The premier meeting on #Crypto meningitis pic.twitter.com/cGD05QQYa1

— David Boulware, MD MPH (@boulware_dr) September 27, 2021

[dhbuzz]

https://stocksregister.com/2021/09/24/matinas-biopharma-holdings-inc-amex-mtnb-a-stock-worth-watching/

[vdt]

Long term MTNB will have great benefits!
Easily spring back to $2.22 in January 2021
-----------------------
"Matinas Biopharma Hl (MTNB) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 80 means that our comprehensive methodology rates Matinas Biopharma Hl above 80% of stocks"

[dhbuzz]

https://www.investorsobserver.com/news/stock-update/premarket-mover-matinas-biopharma-holdings-inc-mtnb-up-7-30

[RealFooFighters]

Gilead might be able to leapfrog the competition, if only they had access to a technology that could be formulated as a natural, non-toxic and highly efficient intracellular oral treatment, hmmm…

https://www.yahoo.com/news/daily-pill-treat-covid-could-083032667.html

[vdt]

Impressive MTNB run. Exposed well to News!
Biopharma stoCJC easily fly amid the Covid pandemic

[vdt]

Impressive MTNB run. Exposed well to News!
Biopharma stoCJC easily fly amid the Covid pandemic

[AnotherInvestor]

If this is legit, then $3 seems pretty low. If not, $3 seems high unless something pans out, like their flavor of omega 3.

[dhbuzz]

NICE.THANKS Lawman.em

[The Lawman]

Gilead announced results from a double-blind Phase 3 clinical trial which showed that early administration of Remdesivir reduced hospitalizations for Covid-19 by 67%.

More importantly for Matinas Biopharma (MTNB), Gilead also announced it is developing a novel oral treatment for Remdesivir, and hoped to file an INDA with the FDA in early 2022.

Given that, according to Matinas' CEO, Jerry Jabbour, the NIH placed Matinas' LNC version of Remdesivir at the top of the queue, it would be fair to infer that this is the "novel oral treatment" for Remdesivir announced by Gilead.

If so, MTNB will be off to the races when the INDA application is filed with the FDA in early 2022.

[vdt]

MTNB doing great! Hold tight! $3 this year!

[dhbuzz]

Certainly seems to be the most ethical choice.Look to see the step down pretty quickly.

[RealFooFighters]

Let's repeat until it's clear and mainstream

95% survival rate for HIV patients with cryptococcal meningitis at 10 and 18wks with encochleated amphotericin B beats SoC and challengers by 20+ miles

Cohort 2 tells us cohort 4 should succeed with a high probability. Recall patients were sick for weeks before hospitalization so what's an extra 2 days of loading dose of amphotericin B injection replaced by MAT2203 at hospitalization really going to affect. Nothing much. All signs point to MAT2203 doing the bulk work of fungal sterilization of the brain.

You can bet what BPs wouldn't give to provide an oral formulation that works to deliver commonly undruggable treatments for any disease associated to inflammation. I said for years. Many diseases are related to inflammation. Many. Arbutus investors should consider putting one foot in LNC now. Do your DD on (oral) BCS class IV drugs and tell me who else can do it. Extremely few. Thought so (Antihydrogen)

[RealFooFighters]

This week is Fungal Disease Awareness Week!
(David Boulware, MD MPH Retweeted)

Next week is Fungal Disease Awareness Week!

Please join us on Monday Sept 20 at noon EDT for an #OpenMyc chat to discuss all things fungal diseases! #ThinkFungus pic.twitter.com/w8b61BHVqm

— MSGERC (@MSG_ERC) September 17, 2021

[dhbuzz]

Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
September 20 2021 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the nomination of Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors at its 2021 Annual Meeting of Stockholders, scheduled for November 1, 2021.
Ms. Corzo is currently partner at Takeda Ventures, Inc. and previously Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Ms. Corzo is located at Takeda’s R&D hub in Cambridge, Massachusetts.

“We are thrilled to nominate Kathryn to our Board of Directors,” stated Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors, and Chair of the Nominating and Governance Committee. “Kathryn is a highly-regarded biotechnology executive with an extensive record of drug development accomplishments. Her leadership roles and development successes with major pharmaceutical companies will be extremely valuable to our Company as we develop and expand the utilization of our LNC platform delivery technology.”

Ms. Corzo commented, “I am honored to have been nominated to join the Matinas Board of Directors at such an exciting time for the Company. The LNC platform presents a unique and promising opportunity to transform the intracellular delivery of complex molecules and I look forward to working with the Board and the management team to optimize the value and impact of this potentially disruptive technology.”

The Company also announced today that Patrick LePore will not stand for re-election to the Board of Directors at the Company’s Annual Meeting of Stockholders on November 1, 2021.

“On behalf of the Board of Directors and Matinas, I would like to thank Pat LePore for his service to the Company. His leadership, expertise and insight have been invaluable in our efforts to serve the best interests of all of Matinas’ stakeholders these past three years. We wish him the absolute best in the future,” stated Jerome D. Jabbour, Chief Executive Officer of Matinas.

“I am extremely grateful to Jerry and Herb, as well as the entire Board of Directors, for the opportunity to serve the Company as Vice Chairman,” commented Patrick LePore. “With the recently announced positive EnACT data and several other important clinical and strategic milestones in place over the next few quarters, Matinas is extremely well-positioned for the future. Kathryn is a tremendous addition to the Board and her development expertise and scientific acumen will be instrumental in maximizing the opportunity ahead with the LNC platform.”

About Kathryn Penkus Corzo

Kathryn Corzo is a biotechnology executive who has served in senior leadership roles for several leading biotechnology and pharmaceutical companies. Since February 2020, she has been the Head, Oncology Cell Therapy Development at Takeda Pharmaceuticals responsible for leading and overseeing development of Takeda’s Oncology cell therapy pipeline including collaborations with academic and biotech innovation partnerships. Kathryn recently joined Takeda Ventures as a partner. Previously, Kathryn served in various leadership roles at Sanofi Genzyme (2010-2019) where she was Vice President of R&D and Global Program Head for Myeloma from June 2015 through December 2019. She is credited for steering multi-disciplinary teams advancing therapeutic candidates from early proof of concept through pivotal trials, worldwide regulatory approvals, indication expansions and product launches. She also led an initiative to establish Sanofi’s U.S. R&D innovation center and digital accelerator based in Cambridge, MA. Before Sanofi, she successfully built a two-decade career at Hoffmann-La Roche, Roche Molecular Systems, Eli Lilly and Syndax taking on responsibility in R&D operations, global clinical development, medical affairs, business development, market access and brand management across multiple platforms and indications. Kathryn has worked to improve outcomes for cancer patients and played an integral role in the development of 12 innovative investigational drugs and five therapeutic products.

Kathryn holds an M.B.A. from Massachusetts Institute of Technology Sloan School of Management and a B.S. in Pharmacy from Massachusetts College of Pharmacy.

[dhbuzz]

https://www.investorsobserver.com/news/stock-update/should-you-sell-matinas-biopharma-holdings-inc-mtnb-stock-wednesday

[RealFooFighters]

Sept 13th Webcast (H.C. Wainwright)

https://www.matinasbiopharma.com/investors/news-events/ir-calendar/detail/2502/h-c-wainwright-23rd-annual-global-investment-conference

[dhbuzz]

No mention of a reverse split,I like that... finishing out the year is going to be worth the wait IMO.

[RealFooFighters]

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To be held on November 1, 2021

"Only stockholders of record of our common stock at the close of business on September 9, 2021 are entitled to receive notice of and to vote"

https://flashalert.me/?symbol=MTNB&source=SEC&referer=https://stocktwits.com/&url=https://www.sec.gov/Archives/edgar/data/1582554/000149315221023040/formdef14a.htm&s3=MTNB/2021-09-17/17-21-12_000000/DEF%2014A/8c584bd8dab2f508e85af21269530a91/formdef14a.htm

[dhbuzz]

https://stocksregister.com/2021/09/17/things-to-consider-when-buying-matinas-biopharma-holdings-inc-amexmtnb-shares/

[vdt]

Matinas BioPharma MTNB is gonna be a rocket.

--Positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis.

--The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

--In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first ten weeks of antifungal treatment.

--Enrollment in Cohort 3 of EnACT has commenced and is expected to complete by the end of 2021. Cohort 3 is the safety lead-in for Cohort 4, an all-oral MAT2203 treatment regimen.

[vdt]

Matinas BioPharma MTNB is gonna be a rocket, with good news!

--Positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis.

--The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

--In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first ten weeks of antifungal treatment.

--Enrollment in Cohort 3 of EnACT has commenced and is expected to complete by the end of 2021. Cohort 3 is the safety lead-in for Cohort 4, an all-oral MAT2203 treatment regimen.

[vdt]

I hold MTNB tightly till $3.00-- soon this year!
---------------
The 5 analysts offering 12-month price forecasts for Matinas BioPharma Holdings Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 0.90. The median estimate represents a +169.06% increase from the last price of $1.12. The current consensus among 5 polled investment analysts is to BUY stock in Matinas BioPharma Holdings Inc. This rating has held steady since August 2021, when it was unchanged from a BUY rating.

https://money.cnn.com/quote/forecast/forecast.html?symb=MTNB